Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2025-12-24 @ 7:52 PM
NCT ID:
NCT02518204
Eligibility Criteria:
Inclusion Criteria:
* Native English speaker
* Capable and willing to provide informed consent
* Able to use a computer and mouse without assistance
* Limited (\< 3 days) or no experience with Lumosity.com
* Limited (\< 3 days) or no experience with other cognitive training programs (e.g., FitBrains, CogMed)
* Willing to refrain from online cognitive training during the course of the study
* No recent (\<1 years) experience with either computer-based or in-person neuropsychological tests (e.g., WAIS-IV, WISC, Halstead-Reitan Battery, MATRICS, CogState, CNS Vital Signs)
* Good general health assessed via self-reported online physical questionnaire and medical history questionnaire
Exclusion Criteria:
* Illiterate or unable to understand written English sufficiently to comprehend study instructions and consent form
* Uncorrected visual impairment (beyond that required to qualify for a California Driver's License) that may impact the ability to complete assessments (self-report or determined by the clinician)
* Uncorrected auditory impairment that may impact the ability to complete assessments (self-report or determined by the clinician)
* Self-reported clinical diagnosis for primary psychiatric or neurological disorder (e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder, Parkinson's disease, epilepsy)
* Self-reported history of concussion or traumatic brain injury, that is considered clinically significant in the opinion of the investigator (e.g. loss of consciousness ≤ 30 minutes)
* Self-reported diagnosis of mental retardation or pervasive developmental disorder
* Self-reported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other dementia
* Self-reported history of sustained substance or alcohol abuse or dependence, that is considered clinically significant in the opinion of the investigator (e.g. as defined by DSM-5)
* Self-report that subject is currently taking an antipsychotic, antidepressant, anti-anxiety, or a cognitively-enhancing medication (e.g. Ritalin), or in the last 72 hours, narcotics for pain or other medications that may impact cognitive performance (e.g. sleeping medications/aides or cold/allergy medications)
* Any other significant medical condition that could impact cognitive performance or result in cognitive impairment in the opinion of the investigator
* Score \<28 on the MMSE
* Positive urine test for recent substance use on either testing day
* Breath Alcohol Content of 0.01% or greater on either testing day
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
70 Years
Maximum Age:
89 Years
Study:
NCT02518204
Study Brief:
Protocol Section:
NCT02518204